According to a new research report by RNCOS entitled, “Global Liquid Biopsy Market Outlook 2020”, innovation and technological advancements based on circulating tumor DNA approach are driving the liquid biopsy market. Because cell-free circulating tumor DNA (ctDNA) is a potential surrogate for the entire tumor genome, the use of ctDNA as a liquid biopsy may help to obtain the genetic follow-up data that are urgently needed. Also, as ctDNA is a bit more abundant in the blood stream than CTC and a number of assays are under clinical trials are being developed to test ctDNA, it is expected that over the forecast period, ctDNA will account for the largest share of revenue.

The Global liquid biopsy market for circulating tumor DNA based tests is expected to reach US$ 657.4 Million by 2020. This can be attributed to high number of laboratory tests performed and companies growing interest towards circulating tumor DNA approach. There is currently an intensive research effort to understand the utility of circulating tumor DNA in various clinical fields such as cancer research, non-invasive prenatal testing and transplant rejection diagnostics.

Circulating tumor DNA levels differentiate early advanced tumors in a wide variety of cancers. Researchers found that circulating tumor DNA was detectable in over 75% of advanced pancreatic, ovarian, colorectal, bladder, gastro-esophageal, breast, melanoma, hepato-cellular, and head and neck cancers.

Future researches have shown strong preference for circulating tumor DNA, among the various biomarkers used for liquid biopsy. Most of the current research and commercialization are also inclined towards circulating tumor DNA.

Circulating tumor DNA is now majorly preferred as it is a noninvasive real-time biomarker that can provide diagnostic and prognostic information before, during treatment and at progression. These include DNA mutations, epigenetic alterations and other forms of tumor-specific abnormalities such as microsatellite instability and loss of heterozygosity.

Monitoring circulating tumor DNA is expected to provide clinicians with faster, cheaper, less invasive ways to assess cancer patients' clinical status and response to therapy. Circulating tumor DNA assay for multiple genes via next-generation sequencing might turn out to be a liquid biopsy alternative to invasive tissue biopsy. The ability to isolate this circulating tumor DNA gives physicians greater insights about cancer mutations and how they react to treatment.

Circulating tumor DNA detection has great potential in cancer diagnose, monitoring, predicting survival. Multigene panel analysis of Circulating tumor DNA may lead to increased test sensitivity. Consequently, the development of appropriate biomarkers and more accurate detection methods based on circulating tumor DNA could benefit a lot to cancer patients and may as a result improve the clinical outcome in the near future. At present, advanced technologies have turned precise circulating tumor DNA mutation detection to reality.

For FREE SAMPLE of this report visit: http://rncos.viewpage.co/Global-Liquid-Biopsy-Market-Outlook-to-2020

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

ABOUT RNCOS

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.